Cinclus Pharma Holding AB (publ) (CINPHA.ST)
Stockholm · SEK · Healthcare · Drug Manufacturers - Specialty & Generic
SEK 11.96 (-0.33%) as of
Key statistics
- Market cap
- 556.59M
- Forward P/E
- -2.12
- EPS (TTM)
- -5.78
- Dividend yield
- 0.00%
- 52-week range
- 10.48 – 19.64
- Beta
- 0.03
- Revenue (TTM)
- 35.18M
- Profit margin
- 0.00%
- Analyst target
- SEK 45.25
- Volume
- 34.32k
About Cinclus Pharma Holding AB (publ)
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Stockholm, Sweden
- Employees
- 17
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.